InnoCan Pharma Corporation (CSE:INNO)

Market Cap	52.64M
Revenue (ttm)	42.36M
Net Income (ttm)	-2.64M
Shares Out	292.42M
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,500
Average Volume	24,141
Open	0.1700
Previous Close	0.1800
Day's Range	0.1700 - 0.1700
52-Week Range	0.1500 - 0.3300
Beta	3.01
RSI	47.83
Earnings Date	Mar 31, 2025

About InnoCan Pharma

InnoCan Pharma Corporation, a pharmaceutical technology company, focuses on the development of various drug delivery platforms combining cannabidiol (CBD) with other pharmaceutical ingredients in the United States, Canada, Europe, and internationally. The company operates in two segments, Pharmaceuticals and Consumer Wellness. It engages in the research and development of CBD loaded exosomes, as well as operates LPT CBD-loaded liposome platform that facilitates exact dosing and the prolonged and controlled release of CBD into the blood stream f...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2018
• Country: Canada
• Stock Exchange: Canadian Securities Exchange
• Ticker Symbol: INNO

Financial Performance

In 2024, InnoCan Pharma's revenue was $29.44 million, an increase of 115.55% compared to the previous year's $13.66 million. Losses were -$1.83 million, -60.98% less than in 2023.

Financial numbers in USD